• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Phenobarbital vs Lorazepam in Alcohol Withdrawal
RESEARCH UPDATE

Phenobarbital vs Lorazepam in Alcohol Withdrawal

October 31, 2022
Clayton Barnes, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Barnes Clayton, MD. Dr. Barnes, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Hawa F et al, Cureus 2021;13(2):e13282        

TYPE OF STUDY: Multisite retrospective cohort study        

Benzodiazepines such as lorazepam (Ativan) and chlordiazepoxide (Librium) have long been considered the gold standard treatment for alcohol withdrawal syndrome (AWS). However, phenobarbital may have advantages over benzodiazepines. Phenobarbital’s gradual time of onset minimizes reinforcing effects; its very long half-life (100 hours) prevents breakthrough withdrawal symptoms between doses; and it is generally safe in liver disease. Prior trials have shown that benzos and barbiturates are both effective for AWS management, but how does phenobarbital actually compare with benzos in clinical settings when it comes to length of stay (LOS)?        

This three-site, retrospective cohort study compared outcomes between patients with AWS who were treated with lorazepam versus phenobarbital. Investigators pooled 606 patients admitted for alcohol intoxication or withdrawal across three sites. The primary outcome was LOS, and secondary outcomes were 30-day readmissions (all-cause and alcohol-related), 30-day emergency department visits, and need for ICU transfer.        

543 lorazepam-treated patients and 63 phenobarbital-treated patients were included in the analysis. The two groups were similar in terms of demographics and in their medical and psychiatric comorbidities. Investigators found that the phenobarbital group had a statistically significant decrease in LOS relative to the lorazepam group (2.8 vs 3.6 days, p<0.001). The phenobarbital cohort also demonstrated a statistically significant reduction in 30-day all-cause readmissions (11% vs 14%), 30-day alcohol-related readmissions (10% vs 12%), and 30-day emergency department visits (11% vs 19%).        

There were several limitations to this study. First, there were many more patients in the lorazepam group, creating potential for systematic statistical error. The retrospective nature of the study meant that investigators could not control for preferences and biases. Severely ill patients were not included in the analysis; those requiring ICU care or addiction medicine consultation were excluded, potentially limiting the study findings to milder AWS cases. And finally, the skewed demographics (68% of the patients were male and 93% were White) might limit the generalizability of the results.        

Carlat Take        

This study suggests that phenobarbital is a reasonable alternative to lorazepam for AWS, with an added possible advantage of shorter LOS and lower 30-day readmission rates. As an already established treatment, using phenobarbital for AWS management is a reasonable consideration for inpatient settings, as long as it is managed by someone familiar with its use. 

Addiction Treatment Research Update
KEYWORDS addiction alcohol detoxification withdrawal
    Clayton Barnes, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: October 31, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Trauma and Addiction
    Integrating Trauma-Informed Care into Addiction Treatment
    Office-Based Opioid Treatment
    Phenobarbital vs Lorazepam in Alcohol Withdrawal
    CME Post-Test - Trauma-Informed Care, CATR, November/December 2022
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.